Open Outbreak

Should I be worried about Antimicrobial resistance?

Updated · Graded from official assessments; nothing here is medical advice.

Antimicrobial resistance · Attention: elevated

If you are in the affected area no assessment
No agency has published an assessment for people in affected areas covering antimicrobial resistance as a whole. UKHSA’s 12 November 2026 update for England and PAHO’s 18 November update for the Americas describe resistance trends.
If you are elsewhere in the same country or region no assessment
No agency has published an assessment for people elsewhere in the same country or region covering antimicrobial resistance as a whole. The official updates for England and the Americas describe historical surveillance findings, not a single current outbreak.
If you are travelling there soon no assessment
No agency has published an assessment for travellers covering antimicrobial resistance as a whole. WHO’s 31 July 2024 notice concerns resistant hypervirulent Klebsiella pneumoniae specifically, rather than travel risk from all resistant infections.
If you are elsewhere in the world moderate
WHO assessed the global risk from resistant hypervirulent Klebsiella pneumoniae as moderate on 31 July 2024. This is an organism-specific assessment, not a November 2026 assessment of antimicrobial resistance as a whole. According to WHO

What is happening

Antimicrobial resistance is a long-running worldwide problem involving drug-resistant bacteria and fungi, not one outbreak with a single starting date or worldwide case total. In its official update on 12 November 2026, UKHSA reported 21,129 antibiotic-resistant bloodstream infections in England in 2025, with growth slowing to 3.2%, and 2,318 deaths among people with resistant Gram-negative bloodstream infections—not necessarily deaths attributable to resistance. PAHO’s official update on 18 November reported carbapenem resistance in Klebsiella pneumoniae rising from approximately 15% in 2015 to 26% in 2024 across 15 reporting countries in Latin America and the Caribbean, describing historical surveillance rather than new November infections. Media coverage reports a projection of 39 million deaths over 25 years, unverified, which must not be read as deaths newly recorded this month. UKHSA and PAHO describe responses including stronger surveillance and laboratories, infection prevention, appropriate antimicrobial use and access to effective medicines.

Who is affected and how it spreads

Antimicrobial resistance means bacteria or fungi are no longer reliably stopped by medicines that used to work; it affects many different infections rather than one disease. Resistant germs can spread between people through the same routes as their non-resistant forms, including direct contact, healthcare-associated spread and, for some organisms, community spread. Candida auris is a healthcare-associated fungus described as highly transmissible, while WHO reports hypervirulent Klebsiella pneumoniae in all six WHO regions. How serious an infection becomes depends on the organism, the infection site, the person’s risk factors and whether effective treatment is available.

What we are watching

Updates

Sources